Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins

References

Page 1

	Year	Citations
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Takashi Yokota, Diane E. Milenic, Marc Whitlow, PubMed Single-chain Antigen-binding ProteinsImmunologyImmunoeditingPathologyImmunodominance	1992	826
Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs Aïcha Demidem, Tammy Lam, Steve Alas, Cancer Biotherapy and Radiopharmaceuticals	1997	397
Phase I immunotoxin trial in patients with B-cell lymphoma. E S Vitetta, Marvin J. Stone, P L Amlot, PubMed ImmunodeficienciesImmunologyImmunoeditingPathologyVascular Leak Syndrome	1991	286
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy PL Amlot, M L STONE, David Cunningham, Blood	1993	219
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy P L Amlot, MJ Stone, David Cunningham, Blood	1993	188
Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. Dario Campana, George Janossy, M Bofill, The Journal of Immunology	1985	184
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study EA Sausville, Donna Headlee, M Stetler-Stevenson, Blood	1995	164
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma MJ Stone, EA Sausville, JW Fay, Blood	1996	139
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Richard A. Messmann, Ellen S. Vitetta, Donna Headlee, PubMed ImmunologyPathologyMetronomic ChemotherapyImmunotherapyOncology	2000	120
Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Maria‐Ana Ghetie, Richard May, Mark Till, PubMed ImmunologyImmunoeditingPathologyImmunologic MechanismHd37 Antibodies	1988	118

Page 1